HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User

Description

List of Tables

The HLA Typing for Transplant Market was valued at USD 998.31 million in 2023, expected to reach USD 1,086.39 million in 2024, and is projected to grow at a CAGR of 9.09%, to USD 1,836.58 million by 2030.

HLA typing for transplant is a crucial procedure in medical science that involves matching the human leukocyte antigens (HLA) of organ and tissue donors with those of recipients to ensure compatibility and reduce the risk of rejection. This process is vital in organ transplantation, including kidney, liver, heart, and bone marrow transplants, where precise matching can significantly influence the success rate and longevity of the transplant. The market for HLA typing is primarily driven by the rising incidence of organ failure and the increasing demand for organ transplants globally. Additionally, advancements in technology, particularly in molecular diagnostics, have enhanced the precision and efficiency of HLA typing, propelling its application in both hospitals and research laboratories. Key growth influencers include the rising awareness about organ donation, increasing government initiatives supporting transplantation activities, and the growing prevalence of chronic diseases leading to organ failure. However, challenges such as the high cost of HLA typing procedures, limited availability of organs, and ethical concerns surrounding organ transplantation act as restraints to market growth. Nevertheless, opportunities abound in the sector, particularly with the advancements in next-generation sequencing and the scope for personalized medicine. Companies poised to innovate in fields like automated and high-throughput HLA typing technologies may gain a competitive edge. Expansions in emerging markets, where healthcare infrastructure is rapidly improving, also present lucrative opportunities for market players. Despite these potential gains, stringent regulatory frameworks and the complexity of matching processes remain significant hurdles. Future research could focus on optimizing cost-effective techniques and improving the speed of HLA matching to enhance accessibility and efficiency. The market is characterized by a continuous demand for innovation and technological advancements, suggesting that companies investing in R&D and adopting digital healthcare solutions will likely lead in capturing market share.

KEY MARKET STATISTICS
Base Year [2023]	USD 998.31 million
Estimated Year [2024]	USD 1,086.39 million
Forecast Year [2030]	USD 1,836.58 million
CAGR (%)	9.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HLA Typing for Transplant Market

The HLA Typing for Transplant Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising incidence of bone marrow, organ, and blood transplant processes
- Adoption of HLA typing in personalized medicine for reduced graft rejections
Market Restraints
- Lack of reimbursement and inadequate insurance policies
Market Opportunities
- Technological advancements in the field of transplant diagnostics and HLA-typing methods
- Preference for immunosuppressive therapies to complement HLA typing
Market Challenges
- Concerns regarding the inaccuracy of HLA typing

Porter's Five Forces: A Strategic Tool for Navigating the HLA Typing for Transplant Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HLA Typing for Transplant Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HLA Typing for Transplant Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HLA Typing for Transplant Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HLA Typing for Transplant Market

A detailed market share analysis in the HLA Typing for Transplant Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HLA Typing for Transplant Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HLA Typing for Transplant Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Chugai Pharmaceutical Co., Ltd., CapitalBio Technology Co., Ltd., Pure MHC, LLC, Laboratory Corporation of America Holdings, TCR2 Therapeutics by Adaptimmune Therapeutics PLC, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., Oxford Nanopore Technologies PLC, Pure Protein, LLC, OraSure Technologies, Inc., CareDx, Inc., DiaSorin S.p.A., BAG Diagnostics GmbH, GenDx by Eurobio Scientific Group, TBG Diagnostics Ltd., QIAGEN N.V., HEALIOS K.K., Thermo Fisher Scientific, Inc., Merck KGaA, Illumina, Inc., BGI Genomics Co.,Ltd., Becton, Dickinson, and Company, Hologic, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., STEMCELL Technologies Inc., F. Hoffman-La Roche AG, CeGaT GmbH, Fujirebio, Inc. by H.U. Group Holdings, Inc., Eurofins Scientific SE, Invectys Inc., Creative Biolabs, Inc., ImmunOs Therapeutics AG, Immucor, Inc. by Werfen, S.A., Immatics N.V., T-Cure Bioscience Inc., Agilent Technologies, Inc., and Garuda Therapeutics.

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services.
Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing.
Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation.
Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring.
Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-3D2FD205B873

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
  - 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
- 5.1.2. Restraints
  - 5.1.2.1. Lack of reimbursement and inadequate insurance policies
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
  - 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
- 5.1.4. Challenges
  - 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
- 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
- 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
- 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
- 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. HLA Typing for Transplant Market, by Product & Service

6.1. Introduction
6.2. Instruments
6.3. Reagents & Consumables
6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

7.1. Introduction
7.2. Molecular Assay Technologies
- 7.2.1. PCR-Based Molecular Assays
  - 7.2.1.1. Real-Time PCR
  - 7.2.1.2. Sequence-Specific Oligonucleotide-PCR
  - 7.2.1.3. Sequence-Specific Primer-PCR
- 7.2.2. Sequencing-Based Molecular Assays
  - 7.2.2.1. Next-Generation Sequencing
  - 7.2.2.2. Sanger Sequencing
7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

8.1. Introduction
8.2. Organ Transplantation
8.3. Stem Cell Transplantation
8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

9.1. Introduction
9.2. Diagnostic Applications
- 9.2.1. Antibody Screening
- 9.2.2. Chimerism Monitoring
9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

10.1. Introduction
10.2. Clinical Laboratories & Research Institution
10.3. Hospitals & Transplant Centers
10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
- 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
- 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
- 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
- 14.3.5. BriaCell receives NCI grant for cancer platform development
- 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
- 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
- 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
- 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
- 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
- 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
- 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

Companies Mentioned

1. Takara Bio Inc.
2. Chugai Pharmaceutical Co., Ltd.
3. CapitalBio Technology Co., Ltd.
4. Pure MHC, LLC
5. Laboratory Corporation of America Holdings
6. TCR2 Therapeutics by Adaptimmune Therapeutics PLC
7. Bio-Techne Corporation
8. NeoGenomics Laboratories, Inc.
9. Oxford Nanopore Technologies PLC
10. Pure Protein, LLC
11. OraSure Technologies, Inc.
12. CareDx, Inc.
13. DiaSorin S.p.A.
14. BAG Diagnostics GmbH
15. GenDx by Eurobio Scientific Group
16. TBG Diagnostics Ltd.
17. QIAGEN N.V.
18. HEALIOS K.K.
19. Thermo Fisher Scientific, Inc.
20. Merck KGaA
21. Illumina, Inc.
22. BGI Genomics Co.,Ltd.
23. Becton, Dickinson, and Company
24. Hologic, Inc.
25. Bio-Rad Laboratories, Inc.
26. Lonza Group Ltd.
27. STEMCELL Technologies Inc.
28. F. Hoffman-La Roche AG
29. CeGaT GmbH
30. Fujirebio, Inc. by H.U. Group Holdings, Inc.
31. Eurofins Scientific SE
32. Invectys Inc.
33. Creative Biolabs, Inc.
34. ImmunOs Therapeutics AG
35. Immucor, Inc. by Werfen, S.A.
36. Immatics N.V.
37. T-Cure Bioscience Inc.
38. Agilent Technologies, Inc.
39. Garuda Therapeutics